SIGLEC10 and cancer: The results showed that CD22 levels was significantly upregulated in cholangiocarcinoma (CHOL) and kidney chromophobe (KICH) cancer, and that SIGLEC1, CD22, CD33, SIGLEC7, SIGLEC8, SIGLEC9, and SIGLEC10 levels were upregulated in kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) relative to levels in normal tissue.